Johnson & Johnson announced a proposed $5.5 billion resolution of remaining ovarian talc claims with first payment of up to $3 billion in 2027, conditioned on ~95% claim participation.
Key Highlights:
- Agreement proposes per-claim payments with a $5.5 billion company commitment to resolve remaining ovarian talc litigation.
- First payment of no more than $3 billion scheduled for 2027; no additional payments required before 2028.
- Resolution conditioned on express participation of at least 95% of the remaining claims across MDL and state proceedings.
- Follows MDL court ruling on plaintiffs' inability to prove specific causation after withdrawal of plaintiffs’ experts in bellwether cases.
- Company frames deal as efficient conclusion to 15-year litigation and notes prior settlements of related claims and supplier disputes.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.